Benzinga | Jan 5, 2022 07:01AM EST

Trevi Therapeutics Announces Clinical Trial Updates For Lead Indications

Phase 2 CANAL (Chronic Cough in IPF) Planned Interim Statistical Update 1Q 2022, with Top-Line Data 1H 2022

Phase 2b/3 PRISM (Chronic Pruritus in PN) Enrollment to End January 31, 2022, with Top-Line Data 1H 2022



NEW HAVEN, Conn., Jan. 5, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio(tm) (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi announced that it expects to perform an interim statistical update in the first quarter of 2022 for its ongoing Phase 2 CANAL trial of Haduvio in patients suffering from chronic cough due to idiopathic pulmonary fibrosis (IPF). Trevi also announced that it expects to end enrollment in its Phase 2b/3 PRISM trial for pruritus associated with prurigo nodularis (PN) by January 31, 2022.